

Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use

Published date: Feb. 1, 2012

Technology description

Summary

Tumor Associated Glycoprotein 72 (TAG)-72 is an oncofetal antigen expressed on a majority of human carcinomas, including colorectal, gastric, pancreatic, breast, lung, and ovarian. The murine monoclonal antibody (mAb) CC49 specifically recognizes TAG-72 and has a higher affinity for TAG-72 than its predecessor, B72.3.

The present invention relates to humanized monoclonal antibodies that have high binding affinity for the tumor-associated glycoprotein (TAG)-72 with minimal immunogenicity. This anti-TAG-72 antibody binds to the same epitope as the CC49 murine variant developed at the National Cancer Institute. The variants of CC49 described in this patent application have been shown to have a decreased immune response, with comparable binding affinity, than the parent murine antibodies.

These variants have potential benefits for use in the detection and/or treatment of a range of human carcinomas.

Institution

NIH - National Institutes of Health

联系我们



叶先生

电话: 021-65679356 手机: 13414935137

邮箱: yeyingsheng@zf-ym.com